A Novel Methodology for Assessing Response to Lymphoma Treatment in Real-World Studies – **Real-World Lugano (rwLugano)**

Scott Swain¹, Kristin M. Zimmerman Savill¹, Andrew Klink¹, Parisa Asgarisabet¹, Jill Kaufman¹, Lindsay McAllister¹, Courtney Omary¹, Hsing-Ting Yu¹, Bindu Kalesan¹, JaLyna Laney¹, Nicholas C. Richardson², Marc Theoret³, Fatima Rizvi³, Jonathon Vallejo⁴, Kun Wang⁴, Donna R. Rivera³, Bruce Feinberg¹

¹Cardinal Health, Dublin, Ohio, USA; ²Office of Oncologic Disease, U.S. Food and Drug Administration, Silver Spring, MD; ³Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ³Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ³Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ³Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ³Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ³Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ³Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD; ⁴Oncology Center of Excellence, U.S. Food Administration, Silver Spring ⁴Office of Biostatistics, U.S. Food and Drug Administration, Silver Spring, MD

BACKGROUND

- In lymphoma clinical trials, blinded independent central review (BICR) using the Lugano 2014 criteria is the standard for assessing treatment response.
- Real-world evidence (RWE) can support United States Food and Drug Administration (US FDA) review of cancer drugs. o As BICR is less available (due to feasibility, challenges, and costs of conducting BICR) in the real-world settings, novel methods are needed to standardize assessment of treatment response.
- Physician-charted response is the standard method used for treatment outcome assessment using real-world data (RWD). o To address these limitations, we developed real-world Lugano (rwLugano), an objective, novel RWD-based methodology for assessing lymphoma treatment response.

OBJECTIVE

• To evaluate performance of assessing lymphoma treatment response classified via rwLugano-derived and physician-charted compared to BICR-assessed response.

METHODS

Study design and participants

- A multicenter, retrospective chart review study conducted at 6 sites within the Cardinal Health Oncology Practice Research Network (PRN), a consortium of US-based community oncologists and hematologists.
- The study included patients ≥18 years old with histologically confirmed, diffuse large B-cell lymphoma (DLBCL) treated with chemoimmunotherapy as first-line (1L) therapy.
- Each participating PRN site selected consecutive patients, starting with the earliest eligible, at each practice. — Deidentified data, captured via an electronic case report form (eCRF).
- Digital PET-CT scans were deidentified upon upload to a secure platform.
- All study materials were reviewed by a central Institutional Review Board.

Figure 1. Study endpoints

	Complete Response (CR)		Partial Response (PR)	Stable Disease (SD)	Progressive Disease (PD)	ORI res
•	Response Assessme	ent M	ethods:			

Physician-charted

rwLugano-derived

BICR-assessed

initial response to 1L therapy as charted in the patient medical record. calculated response based on Lugano classification (**Table 1**) components available on pretreatment (baseline) scans compared to scans on-treatment, with at least 1 on-treatment scan performed at initial response. response assigned by 2 independent radiologists by comparing pretreatment (baseline) scan to scans on-treatment with at least 1 on-treatment (1L) scan performed at initial response (Table 1).

Inclusion criteria

- Adults with a diagnosis of DLBCL (with histologic confirmation) between 2015 and 2022.
- Treated with an anthracycline-containing chemoimmunotherapy regimen that includes an anti-CD20 monoclonal antibody. • PET-CT images available at baseline (within 8 weeks prior to 1L therapy initiation) and initial response assessment scan (within 8-24 weeks of initiating 1L therapy).
- At least 6 months follow-up from 1L therapy initiation, including eligible patients who died within this period. **Exclusion criteria**
- Central nervous system (CNS) involvement at the time of DLBCL diagnosis.
- Treated for other malignancies during 1L therapy.
- Enrolled in a clinical trial during 1L therapy
- Treatment response assessment methods
- The Lugano classification, which uses a 5-point scale (i.e., Deauville score) and is based on the standardized uptake value (SUV) of the most metabolically active lesion, assesses treatment response using PET-CT imaging (Table 1).
- rwLugano was derived from Lugano 2014 criteria by using the abstracted EMR data associated with imaging reports and scans. The other 2 response assessment methods are BICR-reported and physician-charted response.
- **Table 1.** Lugano Classification of Response (Simplified)

Modified Lugano 5PS (Deauville Score)	Change from baseline	New lesions	Bone marrow	Lugano response	
1, 2, or 3	Reduced	No	No	CR	
4 or 5	Reduced	No	Reduced	PR	
4 or 5	No charge	No	No change	NR	
4 or 5	Increased	No	Yes	PD	
Any	Any	Yes	Yes	PD	

5PS, 5-point scale based on SUV of most metabolically active lesion: 1) no uptake above background; 2) uptake ≤ mediastinum; 3) uptake > mediastinum but \leq liver; 4) uptake moderately increased compared to liver; 5) markedly increased uptake above liver at any site and/or new lesions. NR, no response.

Outcome

- The primary end point was agreement of physician-charted- and rwLugano-derived CR, each compared to BICR-assessed CR (using Lugano 2014 criteria).
- Secondary endpoints included PR, SD, PD, and ORR and were evaluated via agreement across the 3 assessment methods. **Statistical analysis**
- Lymphoma treatment responses classified as CR were compared using the 3 methods based on percent agreement and concordance (Cohen's kappa [κ]).
- A generalized linear mixed model (GLMM) with a logit link estimated the odds ratio (OR) of CR comparing rwLugano and physiciancharted response to BICR, adjusting baseline characteristics such as provider ID, disease characteristics, stage at diagnosis, anemia, and heart disease.

RR – overall sponse rate

RESULTS

• 178 patients with DLBCL were eligible for study inclusion (**Table 2**).

- Median (P25-75) follow-up from 1L therapy initiation was 25.6 (16.8-43.8) months. Assignment of CR at initial response assessment was proportionately lower for physician-charted (63.5%) compared with rwLugano-
- derived (81.5%) and BICR-reported (83.1%) response (**Tables 3 and 4**).
- rwLugano-derived versus BICR-assessed was 83.7% (Tables 3 and 4).
- than physician-charted response (overall: 71.3%, κ =0.43; CR: 77.0%, κ =0.40).
- GLMM analyses found a statistically significant difference between physician-charted and BICR-assessed CR (Table 6). o Compared to BICR, physician-charted responses had lower CR estimation (OR=0.23; 95%CI:0.12-0.43).
- o Compared to BICR, rwLugano-derived CR was not statistically different (OR=1.19; 95%CI:0.61-2.33). o Other variables significantly associated with treatment response were the physicians, bulky disease, disease stage, anemia, and heart disease (**Table 6**).
- **Table 2.** Baseline patient demographic and clinical characteristics

Age at diagnosis (years), mean (SD) Sex, n (%) Male Female **Race, n (%)** American Indian or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islander White Unknown Ethnicity, n (%) Hispanic or Latino Not Hispanic or Latino Unknown Duration of follow-up from 1L therapy initiation (months), median (P25-

Ann Arbor stage at 1L therapy initiation among patients with known sta Stage I Stage II

Stage III Stage IV

Bulky disease (≥7 cm), n (%)

Participant characteristics

Comorbidities prior to 1L therapy initiation, n (%) Anemia

Heart disease

Table 3. Physician-charted vs BICR-assessed initial response assessment

Agreement between physician- charted and BICR-assessed initial response	BICR-assessed					
Physician-charted	CR	PR	SD/NR	PD		
CR	107	5	0	1		
PR	37	17	1	1		
SD/NR	1	2	1	1		
PD	0	1	1			

Table 4. rwLugano-derived vs BICR-assessed initial response assessment

Agreement between BICR- reported and rwLugano- derived initial response	BICR-assessed				
rwLugano-derived	CR	PR	SD/NR	PD	
CR	134	10	0	1	
PR	10	12	1	2	
SD/NR	2	0	0	1	
PD	2	0	0	3	

The overall percent agreement between physician-charted versus BICR-assessed assignment of initial responses was 71.3%, whereas

Overall and CR agreement with BICR (**Table 5**) was numerically higher for rwLugano-derived (overall: 83.7%, κ=0.50; CR: 87.9%, κ=0.52)

	N=178
	66.4 (12.8)
	105 (59.0) 73 (41.0)
	0 (0) 5 (2.8) 18 (10.1) 0 (0) 137 (77.0) 18 (10.1)
	13 (7.3) 143 (80.3) 22 (12.4)
-P75)	25.6 (16.8-43.8)
age, n (%)	154 (86.5) 24 (15.6) 42 (27.3) 38 (24.7) 50 (32.5)
	35 (19.7)
	49 (27.5) 38 (21.3)

RESULTS

Table 5. Concordance among the 3 methods for in

	Reference = BICR						
ĺ			Kappa/Weighted Kappa (95% CI)				
	Physician-charted CR PR SD/NR PD ORR All response categories CR agreement, % Overall agreement, % rwLugano-derived CR PR SD/NR PD ORR All response categories CR PR SD/NR PD ORR All response categories CR agreement, % Overall agreement, % Overall agreement, % Overall agreement, % Overall agreement, %		0.40 (0.27-0.54) 0.28 (0.14-0.42) 0.23 (-0.17-0.63) 0.43 (0.02-0.84) 0.57 (0.28-0.86) 0.43 (0.30-0.57) 77.0 71.3				
			$\begin{array}{c} 0.52\ (0.35-0.68)\\ 0.44\ (0.24-0.63)\\ -0.01\ (-0.02-0.00)\\ 0.48\ (0.13-0.84)\\ 0.48\ (0.17-0.79)\\ 0.50\ (0.34-0.67)\\ 87.9\\ 83.7\end{array}$				
	·		oer of total patients. of treatment response (within 6 months from initiation of				
	Covariates	OR (95% CI)					
J	Method BICR-reported Physician-assessed rwLugano-derived	Reference 0.23 (0.12, 0.43) 1.19 (0.61, 2.34)					
	Site 02 03 04 06 07 08	Reference 2.31 (0.63, 8.40) 2.31 (0.76, 7.04) 1.68 (0.44, 6.49) 0.12 (0.03, 0.52) 2.35 (0.77, 7.19)					
	Bulky disease No Yes	Reference 0.37 (0.15, 0.90)	·				
	Stage at diagnosis Stage I Stage II Stage III Stage IV Not available	Reference 0.16 (0.03, 0.71) 0.33 (0.07, 1.57) 0.16 (0.04, 0.67) 0.08 (0.02, 0.40)					
	Anemia No Yes	Reference 0.39 (0.17, 0.90)	·				
	Heart disease No	Reference					

CONCLUSIONS

Yes

• rwLugano classification performed similarly to BICR for classifying initial treatment response to 1L DLBCL therapy. Physician-charted response, for lymphoma treatment response assessment, resulted in proportionally fewer estimates of an inital response

of CR compared with BICR.

0.25 (0.11, 0.59)

- Further study is needed to validate these findings.
- Implications of our findings:

NEFEREN LES her RI, Barrington SF, et al. Recommendatio Cheson BD, Fi

2. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.

ACKNOWLEDGEMENTS

This project was supported by the Oncology Center of Excellence, Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) contract number 75F40121C00134 totaling \$749,362 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.

OTHER RELATED POSTERS PRESENTED AT ISPOR

• (CO201) Feasibility of Using Positron Emission Tomography–Computed Tomography (PET-CT) Scans from Real-World Medical Record Data to Support Lymphoma Treatment Response Assessment

Real-World Data

To learn more, scan the QR Code or visit cardinalhealth.com/rwe-abstracts


Copies of this poster are for personal use only and may not be reproduced without written permission from ISPOR® and the author of this poster.



MSR101

nitial response assessment (N=178)	

of treatment) using GLMM



rwLugano is a novel methodology that may be a relevant measure of outcome classification in real-world lymphoma research.

o Though resource intensive, BICR can be a viable nethod for outcome assessment in using RWD when imaging data are available. o When BICR is not feasible in observational research due to lacking capability or resource restraints, wLugano may offer an alternative, annainin construct y

> aluation, staging, and response assess for initia

• (PT29) A Methodologic Solution to Missing Deauville Scores Using Imaging Report Data to Classify Lymphoma Treatment Response in

